News
January 2, 2007 — The US Food and Drug Administration (FDA) warned healthcare professionals last week about additional reports of nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
The Food and Drug Administration (FDA) has approved 2 new macrocyclic gadolinium-based contrast agents (GBCAs), Elucirem ™ (gadopiclenol) and Vueway ™ (gadopiclenol), for use with magnetic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback